AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12514650 — intervention group
Group type: EXPERIMENTAL
Intervention: ACC/AHA guidelines for CABG
Number of subjects: 1219
Study 12514650 — intervention group
Group type: EXPERIMENTAL
Intervention: RAND guidelines for PTCA
Number of subjects: 1219
Study 12514650 — intervention group
Group type: EXPERIMENTAL
Intervention: RAND guidelines for CABG
Number of subjects: 1219
Study 10489396 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit/vegetable diet
Number of subjects: 354
Study 10489396 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination diet
Number of subjects: 354
Study 10489396 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 354
Study 10489396 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination diet in hypertensive subjects
Number of subjects: 354
Study 8942358 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid diet followed by feeding every 20 min (fed state)
Number of subjects: 4
Study 8942358 — intervention group
Group type: COMPARATOR
Intervention: Liquid diet followed by fasting (fasted state)
Number of subjects: 4
Study 8942358 — intervention group
Group type: EXPERIMENTAL
Intervention: 15NH4Cl taken orally every 20 min for 6 h (total 1.5 g)
Number of subjects: 4
Study 8942358 — intervention group
Group type: COMPARATOR
Intervention: Fasted state
Number of subjects: 4
Study 1656145 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate (1600 mg/day)
Number of subjects: 10
Study 1656145 — intervention group
Group type: EXPERIMENTAL
Intervention: GABA (10(‐8)‐10(‐5) M)
Number of subjects: 10
Study 1656145 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscimol (GABAA agonist, 10(‐8)‐10(‐5) M)
Number of subjects: 10
Study 1656145 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen (GABAB agonist, 10(‐8)‐10(‐5) M)
Number of subjects: 10
Study 1656145 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicuculline (GABAA antagonist)
Number of subjects: 10
Study 6203300 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 25
Study 6203300 — intervention group
Group type: COMPARATOR
Intervention: Pseudo-acupuncture
Number of subjects: 25
Study 6203300 — intervention group
Group type: COMPARATOR
Intervention: No-intervention
Number of subjects: 25
Study 27831829 — intervention group
Group type: EXPERIMENTAL
Intervention: ViSC Social Competence Program
Number of subjects: 1377
Study 27831829 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1377
Study 29995794 — intervention group
Group type: EXPERIMENTAL
Intervention: High-energy ESWT (0.210 mJ/mm)
Number of subjects: 30
Study 29995794 — intervention group
Group type: COMPARATOR
Intervention: Low-energy ESWT (0.068 mJ/mm)
Number of subjects: 30
Study 29995794 — intervention group
Group type: EXPERIMENTAL
Intervention: Both high-energy and low-energy ESWT
Number of subjects: 30
Study 27658839 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient psychotherapy (N=21) including eye movement desensitization and reprocessing (EMDR)
Number of subjects: 38
Study 27658839 — intervention group
Group type: COMPARATOR
Intervention: Outpatient clinical management (N=17)
Number of subjects: 38
Study 27658839 — intervention group
Group type: COMPARATOR
Intervention: Comparison between inpatient psychotherapy and outpatient clinical management
Number of subjects: 38
Study 24508417 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl Ethypharm (FE)
Number of subjects: 73
Study 24508417 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 21963069 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrathin colonoscope (UTC)
Number of subjects: 1121
Study 21963069 — intervention group
Group type: COMPARATOR
Intervention: Standard colonoscope (SC)
Number of subjects: 1121
Study 19759186 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy with concurrent chemotherapy
Number of subjects: 742
Study 19759186 — intervention group
Group type: COMPARATOR
Intervention: Preoperative radiotherapy without concurrent chemotherapy
Number of subjects: 742
Study 17913002 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% Zinc + 0.025% Chlorhexidine mouthrinse
Number of subjects: 10
Study 17913002 — intervention group
Group type: COMPARATOR
Intervention: Control formulations (various enzymes and antibacterial agents)
Number of subjects: 10
Study 17348891 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP plus autologous bone
Number of subjects: 16
Study 17348891 — intervention group
Group type: COMPARATOR
Intervention: Autologous bone
Number of subjects: 16
Study 15003976 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal antitetanus immunoglobulin
Number of subjects: 120
Study 10796930 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise prior to imaging (1 minute of arm swinging)
Number of subjects: 41
Study 10796930 — intervention group
Group type: COMPARATOR
Intervention: No exercise (preexercise imaging)
Number of subjects: 41
Study 9106921 — intervention group
Group type: EXPERIMENTAL
Intervention: Conformal treatment with customized blocks, median high-dose volume (HDV) of 689 cm3
Number of subjects: 266
Study 9106921 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment with rectangular fields, median high-dose volume (HDV) of 792 cm3
Number of subjects: 266
Study 8258043 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidronate 10 mg/kg/day
Number of subjects: 94
Study 8258043 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 3700590 — intervention group
Group type: EXPERIMENTAL
Intervention: Slide-tape counseling format
Number of subjects: 61
Study 3700590 — intervention group
Group type: EXPERIMENTAL
Intervention: Group counseling format
Number of subjects: 61
Study 3700590 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual counseling format
Number of subjects: 61
Study 3700590 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiovisual counseling format
Number of subjects: 61
Study 3700590 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic counseling overall
Number of subjects: 61
Study 31296516 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical stabilisation
Number of subjects: 0
Study 31296516 — intervention group
Group type: COMPARATOR
Intervention: Non-surgical management
Number of subjects: 0
Study 28738258 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (n=80)
Number of subjects: 154
Study 28738258 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus chemotherapy (n=74)
Number of subjects: 154
Study 25642663 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory event-related potentials (AERP) measures
Number of subjects: 70
Study 25642663 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal brain damage
Number of subjects: 70
Study 25642663 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal morbidity
Number of subjects: 70
Study 25642663 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational age and brain damage
Number of subjects: 70
Study 23213105 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant whole-brain radiotherapy (WBRT)
Number of subjects: 0
Study 23213105 — intervention group
Group type: COMPARATOR
Intervention: Observation only
Number of subjects: 0
Study 21241286 — intervention group
Group type: EXPERIMENTAL
Intervention: Perpetrator's group with a norm to be unkind
Number of subjects: 0
Study 21241286 — intervention group
Group type: EXPERIMENTAL
Intervention: Perpetrator's group with a norm to be kind
Number of subjects: 0
Study 21241286 — intervention group
Group type: EXPERIMENTAL
Intervention: Target's group
Number of subjects: 0
Study 21241286 — intervention group
Group type: EXPERIMENTAL
Intervention: Third party group
Number of subjects: 0
Study 21241286 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 19285200 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone Mineral Density (BMD) testing
Number of subjects: 0
Study 19285200 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoporosis risk-assessment tools (e.g., WHO fracture-risk algorithm)
Number of subjects: 0
Study 16254147 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose DAT (daunorubicin, cytarabine, and thioguanine)
Number of subjects: 418
Study 16254147 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose DAT (daunorubicin, cytarabine, and thioguanine)
Number of subjects: 418
Study 16254147 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidation with CsA
Number of subjects: 418
Study 16254147 — intervention group
Group type: COMPARATOR
Intervention: Consolidation without CsA
Number of subjects: 418
Study 14501959 — intervention group
Group type: EXPERIMENTAL
Intervention: Drotrecogin alfa (activated)
Number of subjects: 1690
Study 14501959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1690
Study 10716478 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (200 mg per day) with oral anticoagulants (OAC)
Number of subjects: 229
Study 10716478 — intervention group
Group type: COMPARATOR
Intervention: OAC alone
Number of subjects: 229
Study 9322479 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg plus droperidol 1.25 mg (Group D2)
Number of subjects: 270
Study 9322479 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg plus metoclopramide 10 mg (Group M2)
Number of subjects: 270
Study 9322479 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg plus granisetron 40 micrograms/kg (Group G2)
Number of subjects: 270
Study 9322479 — intervention group
Group type: COMPARATOR
Intervention: Droperidol 1.25 mg (Group D1)
Number of subjects: 270
Study 9322479 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide 10 mg (Group M1)
Number of subjects: 270
Study 9322479 — intervention group
Group type: COMPARATOR
Intervention: Granisetron 40 micrograms/kg (Group G1)
Number of subjects: 270
Study 1534256 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (6 g per day of 85% EPA and DHA)
Number of subjects: 156
Study 1534256 — intervention group
Group type: COMPARATOR
Intervention: Corn oil (6 g per day)
Number of subjects: 156
Study 3884224 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (75 mg twice a day)
Number of subjects: 8
Study 3884224 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulindac (200 mg twice a day)
Number of subjects: 8
Study 30394347 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine with dexmedetomidine (2 μg/mL)
Number of subjects: 52
Study 30394347 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine with epinephrine (1:100,000 dilution)
Number of subjects: 52
Study 29873874 — intervention group
Group type: EXPERIMENTAL
Intervention: Super-mini percutaneous nephrolithotomy (SMP)
Number of subjects: 160
Study 29873874 — intervention group
Group type: COMPARATOR
Intervention: Retrograde intrarenal surgery (RIRS)
Number of subjects: 160
Study 27707855 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal and model (hearing, sight, and touch)
Number of subjects: 67
Study 27707855 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal and video (hearing and sight)
Number of subjects: 67
Study 27707855 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal (hearing)
Number of subjects: 67
Study 24496455 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulants (OAC)
Number of subjects: 6045
Study 24496455 — intervention group
Group type: COMPARATOR
Intervention: Non-users of oral anticoagulants
Number of subjects: 6045
Study 24496455 — intervention group
Group type: EXPERIMENTAL
Intervention: OAC with antiplatelets (aspirin or clopidogrel)
Number of subjects: 6045
Study 23028549 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous blood transfusion (Sangvia group)
Number of subjects: 216
Study 23028549 — intervention group
Group type: COMPARATOR
Intervention: No use of autologous blood (Control group)
Number of subjects: 216
Study 23028549 — intervention group
Group type: EXPERIMENTAL
Intervention: Sangvia group
Number of subjects: 216
Study 23028549 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 216
Study 23028549 — intervention group
Group type: EXPERIMENTAL
Intervention: Sangvia group and Control group
Number of subjects: 216
Study 20332729 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga exercises
Number of subjects: 26
Study 20332729 — intervention group
Group type: COMPARATOR
Intervention: Classic osteoporosis exercise program
Number of subjects: 26
Study 17541109 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 177
Study 17541109 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy
Number of subjects: 177
Study 15200742 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine 0.5% vaginal gel (CHX-VG), 2.5 g, daily for 7 days
Number of subjects: 90
Study 15200742 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole vaginal tablets 500 mg (M), daily for 7 days
Number of subjects: 90
Study 15200742 — intervention group
Group type: COMPARATOR
Intervention: Clotrimazole (CL) vaginal cream, daily for 7 days
Number of subjects: 90
Study 15200742 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine 0.5% vaginal gel (CHX-VG)
Number of subjects: 90
Study 11270911 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 308
Study 11270911 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 308
Study 11270911 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 308
Study 9692706 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (mean duration 5.7 years, range 0.7-12.5 years)
Number of subjects: 109
Study 9692706 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine H2-antagonists (9 patients)
Number of subjects: 109
Study 9692706 — intervention group
Group type: EXPERIMENTAL
Intervention: No drugs (11 patients)
Number of subjects: 109
Study 9692706 — intervention group
Group type: EXPERIMENTAL
Intervention: Any gastric antisecretory drug (mean duration 10.1 years, range 0.7-21 years)
Number of subjects: 109
Study 8204331 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidelines sent to 30 practices in the intervention group
Number of subjects: 170
Study 8204331 — intervention group
Group type: COMPARATOR
Intervention: No guidelines (control group)
Number of subjects: 170
Study 3659736 — intervention group
Group type: EXPERIMENTAL
Intervention: Late bath + placebo
Number of subjects: 6
Study 3659736 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 6
Study 3659736 — intervention group
Group type: COMPARATOR
Intervention: Early bath
Number of subjects: 6
Study 29901296 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-reductase inhibitor (5-ARI) Pentester 5 mg once daily
Number of subjects: 67
Study 29901296 — intervention group
Group type: EXPERIMENTAL
Intervention: -blocker Fokusin 0.4 mg once a day
Number of subjects: 67
Study 29901296 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with 5-ARI (Penester 5 mg once daily) and blocker (Fokusin 0.4 mg once daily)
Number of subjects: 67
Study 29901296 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy (either Pentester or Fokusin)
Number of subjects: 67
Study 25496338 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 122
Study 25496338 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 24103254 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 0
Study 24103254 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA (125 mg)
Number of subjects: 0
Study 24103254 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (60 mg)
Number of subjects: 0
Study 24103254 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate and MDMA (combined)
Number of subjects: 0
Study 24103254 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA
Number of subjects: 0
Study 23241145 — intervention group
Group type: EXPERIMENTAL
Intervention: WBA/active management advice
Number of subjects: 3851
Study 23241145 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy package of up to six sessions
Number of subjects: 3851
Study 23241145 — intervention group
Group type: COMPARATOR
Intervention: Usual care advice (UCA)
Number of subjects: 3851
Study 23241145 — intervention group
Group type: COMPARATOR
Intervention: Single session of advice from a physiotherapist
Number of subjects: 3851
Study 20123670 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba (120 mg EGb 761 twice daily)
Number of subjects: 3069
Study 20123670 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3069
Study 17187496 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen as an adjunct to standard antipsychotic medication
Number of subjects: 0
Study 17187496 — intervention group
Group type: COMPARATOR
Intervention: Standard antipsychotic medication
Number of subjects: 0
Study 15713726 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 373
Study 15713726 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy
Number of subjects: 373
Study 15713726 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with alendronate and hormone replacement therapy
Number of subjects: 373
Study 15713726 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 373
Study 12016085 — intervention group
Group type: EXPERIMENTAL
Intervention: Shock wave therapy (1000 impulses at 14 kV)
Number of subjects: 43
Study 12016085 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure (control group)
Number of subjects: 43
Study 10560786 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17beta‐estradiol (50 microg/day, transdermal) and norethisterone acetate (2.5 mg/day, orally)
Number of subjects: 200
Study 10560786 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 10560786 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17beta‐estradiol
Number of subjects: 200
Study 8919710 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (400 to 800 mg, mean 683 mg)
Number of subjects: 22
Study 8919710 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 1871801 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 0
Study 1871801 — intervention group
Group type: COMPARATOR
Intervention: CsA and steroids alone
Number of subjects: 0
Study 6355851 — intervention group
Group type: EXPERIMENTAL
Intervention: Free care
Number of subjects: 3958
Study 6355851 — intervention group
Group type: COMPARATOR
Intervention: Insurance plans requiring patient to pay a share of medical bills
Number of subjects: 3958
Study 31271526 — intervention group
Group type: COMPARATOR
Intervention: Etanercept alone
Number of subjects: 0
Study 31271526 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept and methotrexate in combination
Number of subjects: 0
Study 28841667 — intervention group
Group type: EXPERIMENTAL
Intervention: D-aspartic acid (6 g/d)
Number of subjects: 22
Study 28841667 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 28841667 — intervention group
Group type: EXPERIMENTAL
Intervention: D-aspartic acid and Placebo
Number of subjects: 22
Study 25903259 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 120
Study 25903259 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Eating diet
Number of subjects: 120
Study 25903259 — intervention group
Group type: COMPARATOR
Intervention: Both diet groups
Number of subjects: 120
Study 24856802 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic postconditioning (PCON), n=49
Number of subjects: 101
Study 24856802 — intervention group
Group type: COMPARATOR
Intervention: Primary angioplasty alone (non-PCON), n=52
Number of subjects: 101
Study 24856802 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic postconditioning (PCON) in swine model, n=6
Number of subjects: 101
Study 24856802 — intervention group
Group type: COMPARATOR
Intervention: Primary angioplasty alone (non-PCON) in swine model, n=6
Number of subjects: 101
Study 22992377 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo treatment (disguised as a hypnotic) for one week
Number of subjects: 0
Study 22992377 — intervention group
Group type: EXPERIMENTAL
Intervention: Warning about one bogus side effect
Number of subjects: 0
Study 22992377 — intervention group
Group type: EXPERIMENTAL
Intervention: Warning about four bogus side effects
Number of subjects: 0
Study 22992377 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 0
Study 19776136 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa powder with 500 mL skim milk/d (C+M)
Number of subjects: 42
Study 19776136 — intervention group
Group type: COMPARATOR
Intervention: Only 500 mL skim milk/d (M)
Number of subjects: 42
Study 17305650 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg daily)
Number of subjects: 366
Study 17305650 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no treatment)
Number of subjects: 366
Study 17305650 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant vitamins (600 mg vitamin E, 250 mg vitamin C and 20 mg beta‐carotene daily)
Number of subjects: 366
Study 17305650 — intervention group
Group type: EXPERIMENTAL
Intervention: Both aspirin and antioxidant vitamins
Number of subjects: 366
Study 17305650 — intervention group
Group type: COMPARATOR
Intervention: Neither treatment (control group)
Number of subjects: 366
Study 15355623 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral nutrition (EEN)
Number of subjects: 107
Study 15355623 — intervention group
Group type: EXPERIMENTAL
Intervention: Early parenteral nutrition (EPN)
Number of subjects: 107
Study 15355623 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (Control)
Number of subjects: 107
Study 10685992 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant lavage followed by partial liquid ventilation
Number of subjects: 12
Study 10685992 — intervention group
Group type: COMPARATOR
Intervention: Gas ventilation with surfactant lavage
Number of subjects: 12
Study 10685992 — intervention group
Group type: COMPARATOR
Intervention: Partial liquid ventilation alone
Number of subjects: 12
Study 9285285 — intervention group
Group type: EXPERIMENTAL
Intervention: Sferics exposure (10 kHz-sferic, 50 nT, 500 microseconds, 10 minutes duration, pulse repetition rate 7-20 Hz)
Number of subjects: 20
Study 9285285 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 20